CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Celgene Corporation

Joanne Beck, Ph.D., Executive Vice President, Global Pharmaceutical Development & Operations

Celgene BI Solution Drives Analytics, Compliance and Reporting

Joanne Beck

Joanne Beck

The highly-regulated nature of the pharmaceutical industry – coupled with historically siloed organizational models and mergers and acquisitions that introduce disparate operational and IT systems to the enterprise – often presents barriers to change and innovation. Throw in the need to store, organize, analyze, interpret, and report on ever-growing amounts of data from those myriad systems. Then add an evolving focus on quality metrics by regulatory authorities, and it’s clear that business as usual in the pharmaceutical industry will not keep pace in the digital age. A new approach, grounded on innovative IT capabilities, is necessary to succeed and adequately serve patients whose lives depend on existing therapies or who are looking for that next medical breakthrough to treat their life-threatening diseases.


Seeking a BI Solution


Celgene Corporation was determined to find a single business intelligence (BI) solution that would integrate data from multiple operations and quality management systems into a single destination to empower the business and allow end users to more easily navigate and utilize their data. Or as Art Malian, Senior Director, Business Intelligence & Master Data Management, summarized it, “We needed to create a unique, purpose-built data repository to enable integrated reporting, analytics, and data visualizations that support our quality and operations processes.”


According to Paul Daly, Corporate Vice President for Global Quality Operations, “Our previous systems were manual and time consuming, which took away from the time we could spend on analysis and decision-making. In addition, with an eye always on compliance, we recognized the general inherent risks present when data is stored in different systems and of their often heavily manual reporting capabilities.”


Asking the Right Questions


Celgene implemented the Quality Analytics and Decision Support System (QUADS) as a comprehensive data integration and analytics solution. To arrive at this solution, they first had to answer some key questions:


• How do we pull data together from systems that were not designed to talk to one another?


• Will the source system or BI tool require changes to make those connections?


• How do these changes fit into our overall master data management strategy?


• How will the data be used and accessed, and what impact would that have on performance (e.g., real-time access would be beneficial for daily decision-making but could impede overall system performance)?


• What are the validation requirements for data consolidated into a single BI tool?


• Will any broader business practices need to change?


The QUADS team engaged the business owners and technical teams for each source system to address these questions and ensure that end user needs for an intuitive interface, fast performance, and trusted data were met. 


Validation was a critical area where historic paradigms needed to be challenged and robust validation principles applied. Collaboration with the business owners for the source systems allowed for proper understanding and insights on the historic data and the associated business rules employed by the user community for these systems, and also provided the appropriate user scenarios to ensure the data was correctly mapped and calculated.


According to Daly, “The real key was asking the right questions and aligning all of the impacted parties on the BI solution, as well as anticipating additional areas that could be pulled into the solution in the future. I believe that’s the key to determining the success of a solution and what its ultimate value will be for your operations.”


QUADS has yielded new efficiencies in accessing key compliance and operational KPI dashboards, and enabled timely decision making and resource allocation


Realizing the Benefits


The specific goals of QUADS were to replace manual effort, improve data integrity and enable innovation. To date, QUADS has yielded new efficiencies in accessing key compliance and operational KPI dashboards, and enabled timely decision making and resource allocation. The time needed to generate critical, validated reports for management review and regulatory reporting was reduced by several orders of magnitude. QUADS’ modular design will allow for future expansion and its standardized metrics and consistent data interpretation are already helping to support an increasingly data-centric, quality-minded culture within Celgene.


QUADS helped to create a foundation for success and competitive advantage in the digital age by creating a scalable, integrated data layer with key elements from Enterprise Resource Planning (ERP), Quality Management System (QMS), Laboratory Information Management Systems (LIMS), Learning Management (LM), Controlled Document Management, and Service/ Project Management systems, and then overlaying a Business Intelligence and Reporting layer with a single, intuitive user interface and fully validated outputs.


After implementation, Maria Brown, Executive Director of Global GMP/ GDP Compliance and QUADS Project Sponsor, remarked that “QUADS is an amazing enabler that will transform the way we do business.” Paul Daly also reflected that “it’s a transformational application for our organization, and it’s tracking to be the highest ROI value we’ve ever achieved on a quality CAPEX project.”


Summary


As this case illustrates, the advent of systems technologies into the pharma space has opened the doors to new and efficient ways of not only accessing data, but also realizingits power through informative and predictive analytics. Gone are the days of “pull-collate-present.” Data-driven analytics, compliance, and quality are the drivers of best-in-class operations where the true promise is quality to the patient. QUADS is a unique and innovative tool that is helping Celgene keep that promise.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/celgene-bi-solution-drives-analytics-compliance-and-reporting-nwid-68.html